GlassScriptPhysician profile
Julia Niemi
NPI 1750807186
$2,487.59
in general payments reported to CMS, 2019-2025
17 companies · $688 in 2025
The $688 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $535 · 2022: $231 · 2023: $372 · 2024: $662 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.45 | 2021-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $346.32 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $229.47 | 2021-2022 | |
| Exact Sciences Corporation | $176.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $162.12 | 2025 | |
| Lilly USA, LLC | $153.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $92.49 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $68.06 | 2023-2024 | |
| Amgen INC. | $47.49 | 2024 | Krystexxa, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $46.59 | 2021-2025 | |
| Amarin Pharma, INC. | $46.09 | 2021-2022 | |
| Abbott Laboratories | $36.43 | 2024-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.19 | 2021-2024 | Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $26.83 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.17 | 2021 | |
| Ironwood Pharmaceuticals, INC | $19.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Niemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.